(Q45885673)

17 December 2017

title

Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse (English)

1 reference

17 December 2017

author name string

M Takanashi

1

1 reference

17 December 2017

K Oikawa

2

1 reference

17 December 2017

K Sudo

3

1 reference

17 December 2017

M Tanaka

4

1 reference

17 December 2017

K Fujita

5

1 reference

17 December 2017

A Ishikawa

6

1 reference

17 December 2017

S Nakae

7

1 reference

17 December 2017

R L Kaspar

8

1 reference

17 December 2017

M Matsuzaki

9

1 reference

17 December 2017

M Kudo

10

1 reference

17 December 2017

M Kuroda

11

1 reference

17 December 2017

publication date

28 May 2009

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

16

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

page(s)

982-989

1 reference

17 December 2017

Knocking down disease with siRNAs

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

RNA interference in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

RNAi-mediated gene silencing in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Transvascular delivery of small interfering RNA to the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Inhibition of respiratory viruses by nasally administered siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Advances in skin gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Cutaneous gene transfer for skin and systemic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Expression of naked DNA in human, pig, and mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

A direct in vivo approach for skin gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

The immunology of Eta-1/osteopontin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Role of osteopontin in amplification and perpetuation of rheumatoid synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

The skin: its structure and response to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

MicroRNA expression in zebrafish embryonic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Topical matrix-based siRNA silences local gene expression in a murine wound model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Osteopontin small interfering RNA protects mice from fulminant hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

inferred from DOI database lookup

7 January 2021

based on heuristic

Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.66

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/GT.2009.66

1 reference

17 December 2017

Dimensions Publication ID

1009474255

0 references

1 reference

17 December 2017